# A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure

Study · id `cardio:ct-nct03984591` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03984591](<https://clinicaltrials.gov/study/NCT03984591>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03984591

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 7200 participants.

## Technical summary

Registry record NCT03984591. Randomized; no masking; primary purpose treatment. Start 2020-11-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 7200 participants (planned count; ClinicalTrials.gov record NCT03984591, source copy `cardio:ctgov-nct03984591-2023-02-01`, retrieved 2026-10-26)
- Started: 2020-11-01 (actual) (ClinicalTrials.gov record NCT03984591, source copy `cardio:ctgov-nct03984591-2023-02-01`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT03984591, source copy `cardio:ctgov-nct03984591-2023-02-01`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT03984591, source copy `cardio:ctgov-nct03984591-2023-02-01`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT03984591, source copy `cardio:ctgov-nct03984591-2023-02-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03984591-2023-02-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
- Acronym: CROWD-ASPECT
- Condition: Systolic Heart Failure
- Intervention (Drug): Eplerenone
- Intervention (Drug): Spironolactone
- Lead sponsor: Bispebjerg Hospital
- Lead sponsor class: OTHER
- Collaborator: Copenhagen University Hospital, Rigshospitalet
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: Bispebjerg Hospital (`cardio:org-bispebjerg-hospital`)
- Registry lists this organization as a collaborator: Copenhagen University Hospital, Rigshospitalet (`cardio:org-copenhagen-university-hospital-rigshospitalet`)

## Provenance

Content hash: fc7aee21868ba226e5566a0aede8f6e28825ff44e4a582837023b7d5cf083b4c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
